
    
      This is a multi-center, prospective, non-randomized feasibility study including 30 subjects.
      Subjects will receive a safety follow-up evaluation at 30 days (+ two weeks) and an efficacy
      follow-up evaluation at 6 months (+ four weeks).
    
  